Cullinan Therapeutics Inc (CGEM.O): Cullinan Receives FDA Alignment on Registrational Ph2 AML Trial Design; Updated Ph1 Durability Data Now Expected in 4Q26

Research evidence excerpt

Cullinan Therapeutics Inc (CGEM.O): Cullinan Receives FDA Alignment on Registrational Ph2 AML Trial Design; Updated Ph1 Durability Data Now Expected in 4Q26

Cullinan Therapeutics Inc (CGEM.O)

28 July 2026 Citi Research

The Product is made available in Germany by Citigroup Global Markets Europe AG ("CGME"), which is regulated by the

European Central Bank and the German Federal Financial Supervisory Authority (Bundesanstalt fur

Finanzdienstleistungsaufsicht BaFin). Börsenplatz 9, 60313 Frankfurt am Main, Germany.

Unless otherwise specified, if the analyst who prepared this report is based in Hong Kong and it relates to “securities” (as

defined in the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong)), the report is issued in Hong Kong by

Citigroup Global Markets Asia Limited. Citigroup Global Markets Asia Limited is regulated by Hong Kong Securities and Futures

Commission. If the report is prepared by a non-Hong Kong based analyst, please note that such analyst (and the legal entity

that the analyst is employed by or accredited to) is not licensed/registered in Hong Kong and they do not hold themselves out

as such. Please refer to the section “Research Analyst Affiliations / Non-US Research Analyst Disclosures” for the details of the

employment entity of the analysts.

The Product is made available in India by Citigroup Global Markets India Private Limited (CGM), which is regulated by the

Securities and Exchange Board of India (SEBI), as a Research Analyst (SEBI Registration No. INH000000438). CGM is also

actively involved in the business of merchant banking (SEBI Registration No. INM000010718) and stock brokerage ((SEBI

Registration No. INZ000263033) in India, and is registered with SEBI in this regard. Registration granted by SEBI, enlistment